医学
Blinatumoab公司
内科学
耐火材料(行星科学)
肿瘤科
队列
人口
疾病
回顾性队列研究
外科
细胞因子释放综合征
队列研究
免疫疗法
白血病
急性淋巴细胞白血病
总体生存率
挽救疗法
化疗
疾病负担
存活率
骨髓
淋巴细胞白血病
作者
Jose Tinajero,Kim Ngoc Nguyen,Dat Ngo,Vaibhav Agrawal,Haoyue Shan,Jianying Zhang,Paul Koller,Hoda Pourhassan,Lindsey A. Murphy,Yazeed Samara,Shukaib Arslan,Stephen J. Forman,Anthony Selwyn Stein,Guido Marcucci,Vinod A. Pullarkat,Ibrahim Taha Aldoss
摘要
Blinatumomab is approved for the treatment of relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Studies have correlated pre-blinatumomab high disease burden (HDB) [> 50% bone marrow blasts (BMB)] with lower response rates and increased risk for toxicities, including cytokine release syndrome (CRS) and neurotoxicity (NT). While the administration of pre-blinatumomab cytoreductive therapy is an appealing approach, larger studies validating the beneficial effect of this strategy in patients with HDB are lacking. We retrospectively analyzed 148 adult patients with R/R B-ALL treated with blinatumomab. Patients were grouped as low disease burden (LDB, n = 55), HDB without cytoreduction (n = 41), and HDB with cytoreduction (n = 52). The median age for the cohort was 40 years; the majority were males (63%) and Hispanic (73%), and the most common ALL subtype was Ph-like (40%). Patients with HDB with cytoreduction had a significantly higher rate of prior alloHCT (p = 0.041) and more lines of prior therapy (p = 0.006) compared to the other cohorts. Compared to patients with HDB, those with LDB had significantly higher response rates to blinatumomab (p < 0.0001), while rates of CRS and NT were not significantly different. Among patients with HDB, cytoreductive therapy was associated with a significantly lower rate of CRS compared to those who did not receive cytoreduction (p = 0.038). However, cytoreduction had no significant impact on treatment response, MRD negativity, or NT. Patients with B-ALL and HDB remain a challenging population for blinatumomab therapy; while cytoreduction may improve safety by reducing CRS, novel strategies are needed to enhance treatment efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI